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ElectrophysiologyThe aim of the present study was to investigate whether/how the recombinant human cardiac IKs could be
regulated by epidermal growth factor receptor kinase in HEK 293 cells stably expressing hKCNQ1/hKCNE1
genes using the approaches of perforated patch clamp technique, immunoprecipitation and Western blot
analysis. It was found that the broad spectrum isoﬂavone tyrosine kinase inhibitor genistein and the selective
epidermal growth factor receptor kinase inhibitor tyrphostin AG556 suppressed the recombinant IKs, and
their inhibition was countered by the protein tyrosine phosphatase inhibitor orthovanadate. The Src-family
kinase inhibitor PP2 reduced the current, but the effect was not antagonized by orthovanadate.
Immunoprecipitation and Western blot analysis revealed that tyrosine phosphorylation level of hKCNQ1
protein was decreased by genistein or AG556, but not by PP2. These results provide the novel information
that epidermal growth factor receptor kinase, but not Src-family kinases, regulates the recombinant cardiac
IKs stably expressed in HEK 293 cells via phosphorylating KCNQ1 protein of the channel.ulty of Medicine Building, The
Hong Kong, China. Tel.: +852
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
It is well known that protein tyrosine kinases (PTKs) regulate cell
growth and differentiation [1], and also play an important role in the
modulation of ion channels [2]. By the use of tyrosine kinase inhibitors
(e.g. isoﬂavone genistein, tyrphostin compounds) and/or protein
tyrosine phosphatase inhibitor (e.g. orthovanadate), several ionic
channels/currents were found to be regulated by protein tyrosine
kinases, including L-type Ca2+ current (ICa.L) in cardiac myocytes [3],
smooth muscle cells [4], GH3 cells [5], volume sensitive chloride
current (ICl.vol) in dog [6] and in human [7] cardiac myocytes, Na+
current (INa) in cardiac myocytes [8,9] and epithelial cells [10], and K+
currents in mouse Schwann cells [11], and rat cardiac myocytes [12].
In addition, cloned KCNQ K+ channels expressed in CHO cells [13] and
hERG channel stably expressed in HEK 293 cells [14] were also
modulated by PTKs.
However, regulation of the slow delayed rectiﬁer potassium
current IKs by PTKs is not fully understood. In an earlier report, cell
swelling-induced increase of cardiac IKs in dog ventricular myocytes
was prevented by the broad spectrum PTK inhibitor genistein, but not
by its PTK-inactive analogue daidzein, suggesting that PTKs mediate
the augmentation of IKs [15]. Nevertheless, in guinea pig ventricular
myocytes, genistein was found to inhibit IKs in a PTK-independentpathway [16]. Recent reports demonstrated that cardiac IKs in guinea
pig cardiac myocytes and in HEK 293 cells stably expressing KCNQ1/
KCNE1 genes is suppressed by PTK inhibitors (e.g. genistein and
tyrphostin compounds) in a PTK-dependent way [17,18]. However, it
is unclear whether the regulation of cardiac IKs is related to direct
interaction with the channel protein or which speciﬁc PTK is involved.
The present study employed the broad spectrum PTK inhibitor genis-
tein, the Src-family kinase inhibitor PP2, the selective EGFR (epidermal
growth factor receptor) tyrosine kinase inhibitor tyrphostin AG556,
and the protein tyrosine phosphatase inhibitor orthovanadate to
determinewhich speciﬁc tyrosine kinase participates in the regulation
of the recombinant cardiac IKs (hKCNQ1/hKCNE1) stably expressed in
HEK 293 cells using perforated patch technique, immunoprecipitation
and Western blot analysis. Our results demonstrated that EGFR
tyrosine kinase, but not Src-family kinases, modulated the recombi-
nant cardiac IKs via phosphorylating hKCNQ1 protein.2. Materials and methods
2.1. Cell culture
The HEK 293 cell line stably expressing recombinant human
cardiac KCNQ1/KCNE1 channel (IKs) [19] was cultured in Dulbecco's
modiﬁed eagle medium (DMEM, Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum and 100 μg/ml hygromycin
(Sigma-Aldrich, St Louis MO, USA). The cells were seeded on glass
coverslips when used for electrophysiological recording.
Fig. 1. Effect of genistein on the recombinant IKs. A. Time-course of the recombinant IKs
recorded in a typical experiment with 3-s voltage step to +40 from−80 mV, then back
to −40 mV (to recorded IKs tail current) as shown in the inset in the absence and
presence of 30 μM genistein. Original IKs traces at corresponding time points are shown
in right of the panel. B. Voltage-dependent IKs traces recorded in a representative cell
with 3-s voltage steps to between−60 and+60 mV from−80 mV (20-mV increment,
0.05 Hz), then to −40 mV (inset) in the absence and presence of 30 μM genistein.
Genistein reversibly inhibited the voltage-dependent current. C. Mean percent value of
the recombinant IKs (at +40 mV) inhibition by 3, 10, 30 and 100 μM genistein. The
number in the parenthesis indicates the experimental number. *P<0.05; **P<0.01 vs
control.
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Tyrode solution contained (mM)NaCl 140, KCl 5.4,MgCl2 1.0, CaCl2
1.8, NaH2PO4 0.33, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) 10.0 and glucose 10 (pH was adjusted to 7.3 with
NaOH). The pipette solution contained (mM) KCl 20, K-aspartate 110,
MgCl2 1.0, and HEPES 10.0, pH was adjusted to 7.2 with KOH. The
antibiotic amphotericin B (Sigma-Aldrich) was freshly added into the
pipette solution (160–200 µg/ml) for perforated patch conﬁguration
[19].
3-(4-Chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]
pyrimidin-4-amine (PP2) was purchased from Tocris (Bristol, UK).
All other reagents were obtained from Sigma-Aldrich. Stock solutions
were made with dimethylsulfoxide (DMSO) for genistein (100 mM),
daidzein (100 mM), tyrphostin AG556 (AG 556) (100 mM), and PP2
(20 mM). The stocks were divided into aliquots and stored at−20 °C.
Sodium orthovanadate stock solution (100 mM) was made with
distilled water, and pH value was adjusted to 9.0.
2.3. Electrophysiology
Cells on a coverslip were transferred to an open cell chamber
mounted on the stage of an inverted microscope and superfused with
Tyrode solution at a rate of ∼2 ml/min. Borosilicate glass electrodes
(1.2-mm OD) were pulled with a Brown–Flaming puller (model P-97,
Sutter Instrument, Novato, CA, USA) and had tip resistances of 1–2 MΩ
when ﬁlled with the pipette solution. The currents were measured
using an EPC-10 ampliﬁer and Pulse software (Heka Elektronik,
Lambrecht, Germany). A 3-M KCl–agar bridge was used as the
reference electrode. The tip potential was zeroed before cell contact,
the patch pipette solution contained 160–200 μg/ml amphotericin B to
make perforated conﬁguration. Access resistance gradually decreased,
and became stable within 30 min. Only cells with constant series
resistance (10–15 MΩ) were accepted for further study [19]. Electrical
signalswere low-passﬁltered at 5 kHz and stored in the hard disk of an
IBM compatible computer. All experiments were performed at room
temperature (22–23 °C).
2.4. Immunoprecipitation and Western blot
The immunoprecipitation and Western blot analysis were per-
formed as previously described [9,14]. The HEK 293 cells stably
expressing hKCNQ1/hKCNE1 genes were treated respectively with
equivolume DMSO (control), 30 μM genistein, genistein plus 1 mM
orthovanadate, 30 μM AG556, AG556 plus 1 mM orthovanadate,
1 mM orthovanadate, or cells with serum-free culture for 36 h, or
the starved cells treated with 100 ng/ml EGF at room temperature.
Following centrifugation at 4 °C, the cell pellet was lysedwith the lysis
buffer containing (mM) 25 Tris, 150 NaCl, 100 NaF, 1.0 EDTA, 1.0
orthovanadate, 1.0 phenylmethylsulfonyl ﬂuoride, 1% Na deoxycholate,
0.1% SDS, 1% Triton X-100, 1 µg/ml leupeptin, and 1 µg/ml aprotinin.
Protein quantiﬁcation of lysates was made using a protein assay reader
(Bio-Rad Laboratories, Hercules, CA), and diluted to equal concentra-
tions. Proteinswere immunoprecipitated overnight at 4 °C using 2 μg of
anti-KCNQ1 antibody (sc-20816, Santa Cruz Biotech, Santa Cruz, CA)
and 100 µl of protein A beads (16-125, Millipore, Billerica, MA).
Immunoprecipitated proteins bound to pelleted protein A beads were
washed thoroughly in PBS, denatured in Laemmli sample buffer,
separated using SDS-PAGE, and electroblotted onto nitrocellulose
membranes. The immunoblots were probed with anti-pTyr-100
antibody (1:1000, Cat. 9411, Millipore, Billerica, MA) overnight at 4 °C
in a blocking solution containing 5% BSA in TBS and Tween 20, and
subsequently treated with goat anti-mouse IgG-HRP antibody (1:5000,
Santa Cruz Biotech, CA) for 1 h at room temperature. Blots were
developed with enhanced chemiluminescence (ECL, Amersham Bios-
ciences) and exposed on X-ray ﬁlm (Fuji Photo Film GmbH). The blotswere then stripped and reprobed with the anti-KCNQ1 antibody to
determine total KCNQ1 protein. The ﬁlmwas scanned, imaged by a Bio-
Imaging System (Syngene, Cambridge, UK), and analyzed via GeneTools
software (Syngene) [14].
2.5. Statistical analysis
Nonlinear curve-ﬁtting was performed using Pulseﬁt (HEKA) and
Sigmaplot (SPSS, Chicago, IL). Paired and/or unpaired Student's t-test
were used as appropriate to evaluate the statistical signiﬁcance of
differences between two group means, and analysis of variance was
used for multiple groups. Group data are expressed as means±SE.
Values of P<0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Effect of genistein on IKs
It was reported that the broad spectrum PTK inhibitor genistein
inhibited cardiac IKs in guinea pig cardiac myocytes [16,17]. We
conﬁrmed whether genistein would reduce the recombinant cardiac
IKs stably expressed in HEK 293 cells. Fig. 1A shows the time-course of
the recombinant IKs recorded in a representative cell with a 3-s
voltage step to +40 from−80 mV, then back to−40 mV as shown in
the inset in the absence and presence of 30 μM genistein. Genistein
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and the effect recovered upon washout.
Fig. 1B displays the voltage-dependent recombinant IKs traces
recorded with 3-s voltage steps to between −60 and +60 from
−80 mV (20-mV increments, 0.05 Hz), then back to −40 mV as
shown in the inset. Genistein reversibly inhibited the currents at all
test potentials. Genistein at 30 μM reduced the IKs tail current (at test
potential of +40 mV) to 8.3±0.6 pA/pF (n=8, P<0.01 vs control)
from 15.6±1.3 pA/pF in control, and recovered to 14.6±1.2 pA/pF
upon washout. Kinetics of the recombinant IKs was not affected by
genistein (data not shown). Genistein inhibited the current in a
concentration-dependent manner (Fig. 1C), and the current was
reduced by 11.1±1.1, 25.7±1.6, 52.3±3.7, and 72.6±4.5% with 3,
10, 30, and 100 μM genistein, respectively. These results indicate that
genistein, as in native cardiac myocytes [16,17], inhibits the recom-
binant cardiac IKs expressed in HEK 293 cells.
In an earlier report, the observation of PTK-independent suppres-
sion of guinea pig cardiac IKs by genistein was based on that the PTK-
inactive analogue daidzein produced a signiﬁcant decrease of the
current amplitude [16]. We also found that 100 μMdaidzein induced a
remarkable reduction of the recombinant IKs; however, 30 μM
genistein produced a more pronounced suppression of the current
in the same cell (Fig. 2A). The current inhibition (26.4±4.5%, n=6,
P<0.01 vs control) with 100 μM daidzein was much weaker (Fig. 2A)
than that (Fig. 1C, 52.5±3.7%, n=8) with 30 μM genistein (P<0.01
vs daidzein 100 μM).
The protein tyrosine phosphatase inhibitor orthovanadate was
then employed to observe whether it would antagonize the genisteinFig. 2. Orthovanadate on genistein effect. A. Time-course of the recombinant IKs
recorded in a typical experiment in the absence and presence of 100 μM daidzein or
30 μMgenistein. Original current traces at corresponding time points are shown in right
of the panel. B. Time-course of the recombinant IKs recorded in a representative cell in
the absence and presence of 30 μM genistein and genistein plus 1 mM orthovanadate
(OV). Original current traces at corresponding time points are shown in right of the
panel. C. Histogram shows the mean percent values of IKs.step during control, in the
presence of 30 μM genistein, and genistein plus 1 mM orthovanadate. n=8, **P<0.01
vs control; #P<0.01 vs genistein alone.effect to determine whether the genistein effect on recombinant IKs is
PTK-dependent. Orthovanadate (1 mM) exhibited a slight increase of
the recombinant IKs (n=8, 5.5±3.1%, P<0.05), consistent with the
previous report in guinea pig cardiac myocytes [17]. Fig. 2B displays
the time-course of the recombinant IKs in a typical experiment in the
absence and presence of 30 μM genistein, and genistein plus 1 mM
orthovanadate. Genistein remarkably suppressed the current ampli-
tude, and the effect was countered by co-application of genistein and
orthovanadate. Fig. 2C illustrates the mean percent values of the
recombinant IKs with genistein, and genistein plus orthovanadate.
Genistein (30 μM) reduced IKs.step to 49.2±3.1% of control, and the
co-application of genistein with orthovanadate reversed the effect to
92.5±4.3% (n=6, P<0.01 vs genistein alone). These results suggest
that the recombinant IKs inhibition by genistein is PTK-dependent.
To investigate which speciﬁc PTK is involved in the regulation of
the recombinant IKs, effects of the Src-related kinase inhibitor PP2 and
the highly selective EGFR kinase inhibitor AG556 on the recombinant
IKs and tyrosine phosphorylation level of hKCNQ1 protein are de-
termined in the following experiments.3.2. Effect of PP2 on IKs
To determine whether Src-related PTKs would regulate the
recombinant IKs, we tested the effect of the selective Src-family PTK
inhibitor PP2 on the current amplitude. Fig. 3A shows the time-course
of the recombinant IKs recorded in a representative cell with the
protocol shown in the inset in the presence of PP2. PP2 at 1 μM, a
concentration 200 times higher [20] than the EC50 of inhibiting Src-
related kinases, had no effect on the current. However, PP2 at 20 μM
substantially decreased the current, but the effect could not be
countered by 1 mM orthovanadate (Fig. 3B). The IKs.step was 610.5±
38.7 pA in control, 488.4±37.5 pA (n=6, P<0.01 vs control) with
20 μM PP2, and 505±40.4 pA (P=NS vs PP2 alone) with PP2 plus
1 mMorthovanadate. These results suggest that Src kinasesmaynot be
involved in the regulation of the recombinant IKs channel expressed in
HEK 293 cells.Fig. 3. PP2 effect on the recombinant IKs. A. Time-course of the recombinant IKs
recorded in a representative cell with the protocol shown in the inset during control, in
the presence of 1 μM PP2. Original current traces at corresponding time points are
shown in right of the panel. B. Time-course of the recombinant IKs recorded in a typical
experiment in the presence of 20 μM PP2, and PP2 plus 1 mM orthovanadate (OV).
Original current traces at corresponding time points are shown in right of the panel.
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Fig. 4A shows the time-course of the recombinant IKs recorded in a
typical experiment with the voltage protocol shown in the inset in the
absence and presence of 20 μMAG556 (a highly selective EGFR kinase
inhibitor) [8,9,14], showed a remarkable suppression of the recom-
binant IKs. AG556 produced a signiﬁcant inhibition of the recombinant
IKs, and the effect recovered upon washout.
Fig. 4B displays the voltage-dependent IKs traces recorded in a
representative cell with the voltage protocol shown in the inset. The
IKs tail current at +40 mV was decreased to 10.4±0.8 pA/pF (n=8,
P<0.01 vs control) with 20 μM AG556 from 17.1±1.4 pA/pF of
control, and recovered to 15.1±1.2 pA/pF upon washout. The
concentration response relationship for the inhibition of the recom-
binant IKs by AG556 was evaluated at +40 mV (Fig. 4C). The IKs.step
was reduced by 9.1±0.5, 27.4±1.8, 53.3±2.1 and 67.2±4.1%
(P<0.05 or P<0.01) with 3, 10, 30 and 100 μM AG556, respectively.
These results indicate that the selective EGFR kinase inhibitor AG556,
like genistein, decreased the recombinant IKs.
Fig. 5A shows that the tyrphostin PTK-inactive analogue tyrphostin
63 (A63, 100 μM) had no effect on the recombinant IKs, while AG556
(30 μM) produced a reversible inhibition of the current in a typical
experiment. Similar results were obtained in seven other cells. Fig. 5B
illustrates the time-course of the recombinant IKs recorded in a
representative cell. AG556 at 30 μM induced a substantial decrease ofFig. 4. Effect of AG556 on the recombinant IKs. A. Time-course of IKs recorded in a
representative cell in the absence and presence of 20 μM AG556 with the protocol
shown in the inset. Original IKs traces are shown in right of the panel. B. Voltage-
dependent IKs traces recorded in a representative cell with the voltage protocol as
shown in the inset in the absence and presence of 20 μM AG556. C. Mean percent value
of the recombinant IKs (at +40 mV) inhibition by 3, 10, 30 and 100 μM AG556. The
number in the parenthesis indicates the experimental number. *P<0.05; **P<0.01 vs
control.
Fig. 5. Orthovanadate on AG556 effect. A. Time-course of IKs recorded from a
representative cell with the voltage protocol as shown in the inset in the absence and
presence of 100 μM tyrphostin 63 (A63) or 30 μM AG556. Original current traces at
corresponding time points are shown in right of the panel. B. Time-course of IKs
recorded in typical experiment in the absence and presence of 30 μMAG556 and AG556
plus 1 mM orthovanadate (OV). Original current traces at corresponding time points
are shown in right of the panel. C. Histogram shows the mean percent values of the
recombinant IKs (at +40 mV) during control, in the presence of 30 μM AG556 and after
co-application of AG556 and 1 mM orthovanadate. n=7, **P<0.01 vs control;
#P<0.01 vs AG556 alone.the current, and the effect was fully countered by co-application of
AG556 and 1 mM orthovanadate. Fig. 5C summarizes the mean
percent values of IKs.step (+40 mV) in the absence and presence of
30 μM AG556, and AG556 plus 1 mM orthovanadate. The current was
reduced to 56.5±5.8% of control with 30 μM AG556 (P<0.01 vs
control), and reversed to 95.6±4.2% of control with co-application
of AG556 and 1 mM orthovanadate (P<0.01 vs AG556 alone).
Orthovanadate signiﬁcantly antagonized the inhibition of IKs by the
selective EGFR kinase inhibitor AG556, suggesting that EGFR kinase
participates in regulating the recombinant IKs.
3.4. Effect of EGF on IKs
To further determine the potential regulation of IKs by EGFR kinase,
EGF (100 ng/ml) was directly applied in the bath solution. However,
EGF was unable to enhance the recombinant IKs (n=6, data not
shown). To demonstratewhether it is related to the saturation of basal
tyrosine phosphorylation of the channel, cells were cultured in a
serum-free medium for 36 h. Fig. 6A shows the time-course of the
recombinant IKs (+40 mV) recorded in a representative cell with a 36-
h starvation. The current was gradually increased by application of
100 ng/ml EGF. AG556 (20 μM) inhibited both EGF-induced current
and basal current level. Fig. 6B illustrates the mean percent values of
IKs.step (+40 mV) in the absence and presence of 100 ng/ml EGF, and
EGF plus 20 μM AG556. The current was increased to 114.1±5.6% of
Fig. 6. EGF enhanced the recombinant IKs in cells with serum-free culture. A. Time-
course of IKs recorded in a typical experiment in the absence and presence of 100 ng/ml
EGF and after co-application of EGF and 20 μM AG556. Original current traces at
corresponding time points are shown in right of the panel. B. Histogram showing the
mean percent values of the recombinant IKs (at +40 mV) in cells with a 36-h serum-
free culture during control, in the presence of 100 ng/ml EGF and after co-application of
EGF and 20 μM AG556. n=6, *P<0.05, **P<0.01 vs control; #P<0.01 vs EGF alone.
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to 75.3±6.7% of control (P<0.01 vs EGF alone or control) with co-
application of EGF and 20 μM AG556. These results indicate that basal
tyrosine phosphorylation level of the recombinant IKs is saturated in
cells with normal culture conditions (with 10% FBS) and EGF enhances
the current only in starved cells.
3.5. Tyrosine phosphorylation level of KCNQ1
The tyrosine phosphorylation level of KCNQ1 protein of IKs was
determined with immunoprecipitation and Western blot analysis.
Fig. 7A shows the images of tyrosine phosphorylation level of KCNQ1
with different treatments (30 min). Genistein (30 μM) and AG556
(30 μM) reduced the phosphorylation level of KCNQ1 protein and the
reduction was substantially reversed by co-application of 1 mM
orthovanadate. PP2 (20 μM) did not decrease the tyrosine phosphor-
ylation level. In addition, orthovanadate (1 mM) and EGF (100 ng/ml)
had no effect on the tyrosine phosphorylation level of KCNQ1 in cells
with normal culture conditions. The tyrosine phosphorylation level of
KCNQ1 protein slightly reduced in cells with a serum-free culture for
36 h, and EGF countered the reduced phosphorylation level.
Fig. 7B summarizes the quantitative tyrosine phosphorylation
levels of KCNQ1 protein. The tyrosine phosphorylation level of KCNQ1
protein was 72.8±5.9% and 68.1%±6.7% of control with genistein
and AG556, respectively (P<0.01 vs control). The phosphorylation
level was 91.2±7.7% and 93.6±7.9% of control respectively with
genistein plus orthovanadate and AG556 plus orthovanadate (P<0.05
vs genistein alone or AG556 alone). PP2, orthovanadate, and EGF had
no effect on the phosphorylation of KCNQ1 protein. The serum-free
starvation decreased the phosphorylation level to 90.1±8.7%(P>0.05 vs control), and the reduction was reversed by application
of EGF. These results indicate that the reduction of tyrosine phos-
phorylation in KCNQ1 protein caused by EGFR kinase inhibition can be
countered by inhibiting protein tyrosine phophatases. Basal KCNQ1
tyrosine phosphorylation is saturated; therefore, additional stimula-
tion would not increase the phosphorylation level with EGF or
orthovanadate, and a 36-h serum-free starvation induces a slight
reduction of the phosphorylation in HEK 293 cells stably expressing
hKCNQ1/hKCNE1 genes.
4. Discussion
The slowly delayed rectiﬁer IKs is an important repolarizing current
in mammalian hearts [21,22]. It has been demonstrated that serine/
threonine protein kinases (e.g. PKA and PKC) regulate IKs [23,24].
Activation of PKA by cAMP increases IKs density and produces a rate-
dependent shortening of action potential duration, which underlies
the sympathetic nervous system regulation of cardiac function
mediated by β-adrenergic receptor activation, and pharmacological
therapeutics [25]. In addition, cardiac IKs or recombinant IKs was
regulated by phospholipid phosphatidylinositol-4,5-bisphosphate
(PIP2) [26–28] and calmodulin [29]. Previous reports [15,17,30] and
the present observation provide additional information that cardiac IKs
is regulated by PTKs.
The earliest evidence of IKs regulation by PTKs was reported by
Zhou et al. in dog ventricular myocytes, in which swelling-induced
increase of IKs was counted by the PTK inhibitor genistein, but not by
its PTK-inactive analogue daidzein [15]. However, the later study from
Washizuka et al. showed a PTK-independent suppression of cardiac
IKs by genistein based on the observation that the PTK-inactive
analogue daidzein also signiﬁcantly decreased the current amplitude
[16]. A recent study from Missan et al. conﬁrmed that the genistein-
induced reduction of IKs was PTK-dependent, because the current
inhibition was remarkably antagonized by the protein tyrosine
phosphatase inhibitor orthovanadate [17]. In addition, orthovanadate
also countered the IKs suppression by the inhibitor tyrphostin A23 or
A25 in guinea pig cardiac myocytes [17].
In the present study, we also employed pharmacological tools of
PTK inhibitors, in which the selectivity is relative [2] and nonselective
effect is reported previously [16], to determine the regulation of
recombinant IKs by PTKs; however, the result with a wide range of
concentrations (3–100 μM) of the broad spectrum PTK inhibitor ge-
nistein supports the notion that the suppression of IKs by this inhibitor
is PTK-dependent, since the current inhibition by the selected
concentration (30 μM) of genistein was not only greater than that
by 100 daidzein (a PTK-inactive analogue), but also antagonized by
the protein tyrosine phosphatase inhibitor orthovanadate (Fig. 2). The
further experiments demonstrated that the inhibition of IKs by the
selective EGFR kinase inhibitor AG556 (30 μM), but not the Src-family
kinase inhibitor PP2 (20 μM), was almost fully countered by
orthovanadate (Fig. 5). Therefore, the reduction of IKs by 20 μM PP2
is likely mediated by PTK-independent inhibition, while the AG556
suppression of the current is mediated by EGFR kinase inhibition.
Thus, the new ﬁnding of the present study is that EGFR kinase, but not
Src-related kinases, participates in the regulation of recombinant IKs.
The immunoprecipitation and Western blot analysis further revealed
that PP2 had no effect on tyrosine phosphorylation level of KCNQ1
protein, whereas genistein and AG556 remarkably decreased the
tyrosine phosphorylation level, and the reduced phosphorylation
level was reversed by orthovanadate (Fig. 7). These results suggest
that EGFR kinase, but not Src-related kinases, regulates IKs activity by
phosphorylating α-subunit KCNQ1 protein of the channel.
It has been demonstrated that endogenous EGFRs are present in
HEK 293 cells [31]. Our previous study demonstrated that both EGFR
kinase and Src-related kinases regulate the α-subunit hERG current of
human cardiac IKr [14]; however, it is not the case for the recombinant
Fig. 7. Tyrosine phosphorylation level of recombinant IKs. A. Upper panel, protein lysates were immunoprecipitated with anti-KCNQ1 antibody, Western blots were then prepared
and probed with the anti-phosphotyrosine (Tyr(P)) antibody. Lower panel, Western blots of cell lysates, probed with the anti-KCNQ1 antibody. B. Histogram summarizes the mean
values of the relative levels of tyrosine-phosphorylated KCNQ1 protein analyzed by the densitometry. The density of the immunoprecipitation (as in A) was normalized to that of the
Western blots. Relative phosphorylated protein level (n=4 experiments) is expressed as a percentage of the vehicle control. **P<0.01 vs vehicle control, #P<0.05 vs genistein or
AG556 alone.
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not be countered by the protein tyrosine phosphatase inhibitor
orthovanadate (Fig. 3) and tyrosine phosphorylation level of KCNQ1
protein is not reduced by PP2 (Fig. 7). Our results are supported by the
previous report in which KCNQ1 channel expressed in CHO cells is not
modulated by Src-family kinases [32].
The present observation and previous studies [15,17,30] have
demonstrated that there is no doubt that cardiac IKs is regulated by
PTKs. However, the recent study from Missan and colleagues did not
demonstrate the evidence that IKs channels are directly phosphory-
lated by PTKs based on the results that cells co-expressed KCNE1 with
KCNQ1 mutants at Y51, Y111, Y171, Y184, Y395, Y461, and Y662 with
phenylalanine did not show a remarkable reduction of the channel
inhibition by the PTK inhibitor A25 (compared to that of wild type
KCNQ1) [18]. However, they did ﬁnd that four mutants (at Y51, Y94,
Y111 and Y382) of KCNQ1 showed a trend to decrease the current
inhibition by the PTK inhibitor A25, though the reduction was not
statistically signiﬁcant [18], which is most likely that more than one
tyrosine of the channel is involved in the phosphorylation.
In the present study, the immunoprecipitation and Western blot
analysis provide a strong evidence of KCNQ1 tyrosine phosphoryla-
tion of the recombinant IKs. The phosphorylation level was decreased
by genistein or AG556, and the reduction of the phosphorylation
was countered by the protein tyrosine phosphatase inhibitor
orthovanadate (Fig. 7), indicating direct evidence that IKs is regulated
by EGFR kinase.
Our patch clamp results showed that the recombinant IKs was
enhanced by EGF only in the starved cells cultured with a serum-free
medium for 36-h (Fig. 6), but not in cells cultured with a normal
medium (containing 10% serum). The biochemical experiments also
showed that tyrosine phosphorylation level of the recombinant
KCNQ1 was not enhanced by EGF or orthovanadate in cells cultured
with a normal medium; however, the tyrosine phosphorylation level
was reduced in the cells cultured with serum-free medium for 36-h,
even the reductionwas not statistically signiﬁcance. This suggests that
the basal tyrosine phosphorylation of KCNQ1 subunit in HEK 293 cellsis saturated, and therefore is highly sensitive to the inhibition of EGFR
kinase (Fig. 7).
It is well known that IKs plays an important role in cardiac
repolarization [21,22]. In addition to the regulation by protein kinases
PKA and PKC [23,24], cardiac IKs is modulated by PIP2 [26–28,33] and
calmodulin [29]. Dysfunction of IKs, resulting from either the gene
mutations or cardiac diseases such as chronic heart failure, can induce
inherited or acquired long-QT syndromes which are often associated
with life-threatening arrhythmias in emotional or physical stress [34–
37], which is also related to abnormal phosphorylation of the IKs
channel proteins [38]. Previous studies and the present observation
provide the strong evidence that cardiac IKs could also be modulated
by interaction with protein tyrosine phosphatases and EGFR tyrosine
kinase. However, whether and how the alteration of IKs channel
regulation by protein tyrosine phosphatases and/or EGFR tyrosine
kinase participates in the pathophysiological and electrical remodeling
in cardiac disorders remains to be studied.
Collectively, the present study has demonstrated the novel in-
formation that the recombinant human cardiac IKs stably expressed in
HEK 293 cells is regulated by EGFR tyrosine kinase, but not by Src-
family kinases.
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